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256Objective: Bone morphogenetic protein-2 (BMP-2) is a major regulator of aortic valve calcification. Micro-
RNAs (miRNAs) are essential post-transcriptional modulators of gene expression and miRNA-141 is a known
repressor of BMP-2–mediated osteogenesis. We hypothesized that miRNA-141 is a key regulator of aortic valve
calcification.
Methods: Porcine valvular interstitial cells were isolated, transfected with miRNA-141 or control, and stimu-
lated with transforming growth factor-b. The BMP-2, extracellular signal-regulated kinase 1/2, and runt-related
transcription factor 2 levels were determined by immunoblotting and reverse transcriptase polymerase chain re-
action. To determine the role of miRNA-141 in bicuspid aortic valve disease, human bicuspid (n ¼ 19) and tri-
cuspid (n ¼ 17) aortic valve leaflets obtained intraoperatively were submitted for GenoExplorer human
microRNA array, immunoblotting, and histologic and immunohistochemical analyses.
Results: Stimulation of porcine aortic valvular interstitial cells with transforming growth factor-b induced mor-
phologic alterations consistent with myofibroblastic transformation, BMP-2 signaling, and calcification. Trans-
fection with miRNA-141 restored transforming growth factor-b–induced valvular interstitial cell activation,
BMP-2 signaling, and alkaline phosphatase activity (3.55  0.18 vs 4.01  0.21, P<.05), suggesting upstream
regulation by miRNA-141. miRNA microarray demonstrated differential expression of 35 of 1583 miRNA se-
quences in the bicuspid versus tricuspid aortic valve leaflets, with a 14.5-fold decrease in miRNA-141 in the
bicuspid versus tricuspid leaflets (P<.05). This was associated with significantly increased BMP-2 protein ex-
pression in bicuspid aortic valve compared with the tricuspid aortic valve leaflets (P<.001).
Conclusions:We report a completely novel role of miRNA-141 as a regulator of BMP-2–dependent aortic val-
vular calcification and demonstrate marked attenuation of miRNA-141 expression in patients with bicuspid aor-
tic valve-associated aortic stenosis. Therapeutic targeting of miRNA-141 could serve as a novel strategy to limit
progressive calcification in aortic stenosis. (J Thorac Cardiovasc Surg 2012;144:256-62)Supplemental material is available online.
Aortic valve stenosis, once conceptualized as degenerative
calcification, is now appreciated to be a complex and active
process characterized by endothelial injury, inflammatory
infiltration, angiogenesis, valvular interstitial cell-to-
myofibroblast transformation, calcification, and matrix
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The Journal of Thoracic and Cardiovascular SurgValvular calcification is the defining feature of aortic ste-
nosis (AS), with accumulating evidence for heterotopic os-
sification.2 Human aortic valvular interstitial cells (VICs)
isolated from stenotic aortic valves express osteogenic sig-
nals, notably the bone morphogenetic proteins (BMPs) of
the transforming growth factor-b (TGF-b) family.2,3 The
BMP family of proteins is a regulator of cell growth,
apoptosis, and differentiation of mesechmymal cells into
osteoblasts and chondrocytes.4 These markers are
expressed during active mineralization and osteoblast dif-
ferentiation and tend to co-localize to areas of calcifica-
tion.5,6 Of these, BMP-2 is a potent stimulant of valvular
calcification in vivo and in vitro.3 The downstream elements
of BMP-2 include the transcription factors runt-related
transcription factor 2 (RunX2) and distal-less homeodo-
main 5 (Dlx5).7,8 RunX2 is a transcription factor involved
in the regulation of fibroblast differentiation and bone
formation.9 There are several downstream protein targets,
such as osteopontin, an important matrix glycoprotein of
bone, that is associated with calcification and atherosclero-
sis in human arteries and in a variety of human tissues.10ery c July 2012
Abbreviations and Acronyms
AS ¼ aortic stenosis
BMP-2 ¼ bone morphogenetic protein-2
BAV ¼ bicuspid aortic valve
Dlx5 ¼ distal-less homeodomain 5
miR ¼ microRNA or miRNA
RunX2 ¼ runt-related transcription factor-2
a-SMA ¼ a-smooth muscle actin
TAV ¼ tricuspid aortic valve
TGF-b ¼ transforming growth factor-b
VIC ¼ valvular interstitial cell
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SMicroRNAs (miRNAs) are evolutionarily conserved
22-mer RNA molecules that are emerging as essential
post-transcriptional modulators of gene expression, which
coordinate and integrate multiple regulatory pathways in-
volved in normal and abnormal development. Current pre-
dictions suggest that miRNAs might regulate expression
of approximately 30% of all protein-coding genes at base-
line that increases with stress or injury.11 miRNA-141 is
a key regulator of BMP-2–mediated osteogenesis but its
role in valvular calcification is unknown.12
In the present study, we examined the role of miRNA-141
on regulation of BMP-2–dependent calcification in cultured
VICs. Bicuspid aortic valve (BAV) is a common congenital
cardiac anomaly, with an estimated incidence of 1% to
2%.13 It is responsible for the greatest burden of aortic
valve disease in patients younger than 70 years old in North
America. To determine whether altered expression of
miRNA-141 is associated with early calcification in
BAVs, we performed microRNA profiling. We identify
miRNA-141 downregulation in human BAV versus tricus-
pid aortic valve (TAV) leaflets, which is associated with in-
creased expression of BMP-2 in the areas of valvular
calcification.
METHODS
VIC Culture and Transient Transfection
Aortic VICs were harvested from 10 porcine hearts (4–6months old), as
previously described.14 In brief, aortic valves were excised with care not to
introduce any nonleaflet tissue. The leaflets were gently scraped on the aor-
tic and ventricular aspects to remove the endothelial layer, and the tissues
were then sectioned into pieces approximately 23 2 mm and explant cul-
tured in growth medium (M199 medium with penicillin G, streptomycin,
amphotericin B, and 10% fetal bovine serum) in an incubator supplied
with 5% carbon dioxide for 10 days. The cells growing from the explants
were subcultured, and the cells from passages 3 to 4 were used for addi-
tional study.
Monolayers of VICs (7.5 3 104 cells/cm2) were transfected with 2 nM
of the miRIDIAN mimic microRNA-141 or a scrambled control (Thermo-
Scientific, Waltham, Mass) using the Dharmafect transfection reagent
(Dharmacon, Lafayette, Colo), according to themanufacturer’s recommen-
dations. The transfected cells were further cultured with or without
5 ng/mL TGF-b (R&D Systems, Minneapolis, Minn) for 6 to 12 days inThe Journal of Thoracic and Cathe low serum medium (1% fetal bovine serum supplemented). The me-
diumwas changed every 3 days. The cells were harvested, and the total pro-
tein and RNAwere extracted for analysis.
Study Population and Data Collection
Patients undergoing elective aortic valve replacement for AS at St Mi-
chael’s Hospital from June 2010 to June 2011 were enrolled. The aortic
valve leaflets were obtained intraoperatively from patients with congenital
BAVs (n ¼ 19) and TAVs (n ¼ 17) at valve replacement. The leaflets were
sectioned into 2 equal parts; 1 part was flash frozen in liquid nitrogen and
submitted for RNA or protein extraction, and 1 part was fixed in 10% for-
malin and embedded in paraffin.
The patients were identified as having congenital, and not functional,
BAV using clinical criteria according to the following characteristics: (1)
age younger than 65 years at surgery, (2) a positive history of murmur since
adolescence, (3) a positive family history of BAV, (4) valve leaflet and sinus
asymmetry on the echocardiogram and intraoperatively, and (5) an associ-
ationwith ascending aorta or aortic root dilation. Patients deemed question-
able for having congenital BAV were excluded. Additional exclusion
criteria included a nonstenotic, primary aortic valve regurgitant phenotype,
infective endocarditis, or rheumatic aortic valvulopathy. The St Michael‘s
Hospital institutional review board approved the study, and all patients pro-
vided written informed consent.
miRNA Array
miRNAwas isolated using themiRNeasy kit (Qiagen, Hilden,Germany)
according to the manufacturer’s instructions. For miRNA microarray anal-
ysis, total RNAwas directly labeled with biotin and hybridized to the Gen-
oExplorer microRNA human array containing 1583 human miRNA probes
(Genosensor, Tempe, Ariz), and the fluorescent signals were then scanned
using a GenePix 4000b Biochip. The average of 3 mean fluorescence signal
intensities for each miRNA probe was normalized to that for tRNAmet.
Precursor miRNAs detected at twofold greater than the background were
considered to be expressed. Data were analyzed using GenePix, version
5.0, software (provided byGenoSensor, Temple, Ariz). The complete anno-
tated miRNA microarray raw and normalized dataset is available at the
National Institutes of Health/National Center for Biotechnology Informa-
tion, Gene Expression Omnibus (accession number GSE30197).
Histologic Examination, Terminal Deoxynucleotidyl
Transferase-Mediated Deoxyuridine Triphosphate
Nick End Labeling, and Immunohistochemistry
Formalin-fixed and paraffin-embedded tissues were analyzed using
hematoxylin-eosin, Masson’s trichrome, and von Kossa histochemical
analysis. The tissues were also analyzed with immunohistochemistry
for BMP-2 (Abcam, Cambridge, Mass) and a-smooth muscle actin
(a-SMA). In brief, the sections were washed in Tris-buffered saline/
0.1% Tween-20 then blocked in 5% milk. The sections were incubated
in primary antibody (1:5000) overnight, washed, and then incubated in bio-
tinylated secondary antibody (1:10,000) for 30 minutes. The sections were
treated with Vectastain ABC reagent (Vector, Burlingame, Calif), then
DAB, and counterstained with hematoxylin. ImageJ software (available
from http://rsbweb.nih.gov/ij) was used for signal quantitation.
Real-Time Polymerase Chain Reaction for Detection
of MicroRNA-141, BMP-2, and RunX2 Expression
VIC microRNAs were extracted using the miRNeasy Mini Kit (Qiagen,
ON, Canada) and reverse transcribed with the RT2 miRNA First Strand Kit
(SA Biosciences, Frederick, MD), as per the manufacturer’s instructions.
Real-time polymerase chain reaction was performed on the StepOnePlus
Real-Time Polymerase Chain Reaction System (Applied Biosystems,
Foster City, Calif) using the RT2 SybrGreen quantitative PCR Mastermixrdiovascular Surgery c Volume 144, Number 1 257
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(SA Biosciences), BMP-2 (forward 50-TCTGCGGTCTCCTAAAGGTC-30
and reverse 50-GGAAGCAGCAACGCTAGAAG-30), RunX2 (forward
50-CACACCTACCTGCCACCAC-30 and reverse 50-TCCTGACGAGGT
GCCATAG-30), and glyceraldehyde-3-phosphate dehydrogenase (forward
50-CACCAGGGCTGCTTTTAACTCTGGTA-30 and reverse 50-CCTTGA
CGGTGCCATGGAATTGC-30) primers. Gene expression data were ana-
lyzed using Pfaffl’s relative expression software (REST-MSC, version 2,
available from http://www.wzw.tum.de/gene-quantification/).Alkaline Phosphatase Activity in VICs
The alkaline phosphatase colorimetric assay kit (Abcam, Cambridge,
UK) was used to measure alkaline phosphatase activity in the cell lysate
collected from the transfected or control VICs after stimulation with
TGF-b for 6 days.FIGURE 1. MicroRNA (miRNA)-141 represses valvular interstitial cell
activation and osteoblastic transformation. Transforming growth factor-
b (TGF-b) treatment induced (A) cellular aggregation (arrowheads) and
stellate transformation (arrows), and (B) alkaline phosphatase (ALP) was
repressed by miRNA-141 (mean  standard deviation; n ¼ 5/group).Western Blot
For detection of BMP-2 expression, proteins were isolated from the hu-
man aortic valve leaflets, whichweremechanically disrupted using amortar
and pestle and suspended in lysis buffer containing protease inhibitor cock-
tail (Roche, Basel, Switzerland). The proteins were quantified by the Brad-
ford assay (Pierce/ThermoScientific) using bovine serum albumin as the
standard. Total protein (50 mg) was electrophoresed on 10% polyacryl-
amide gels and transferred onto nitrocellulose membranes (Bio-Rad Labo-
ratories, Hercules, Calif). After blocking with 5% fat-free milk solution,
the membranes were exposed to monoclonal BMP-2 (1:1000; Abcam) pri-
mary antibody and a corresponding rabbit anti-mouse peroxidase-linked
secondary antibody (1:5000; Cell Signaling Technology, Danvers, Mass).
Blots were developed with ECL reagent and exposed on x-ray film. The
films were scanned, and ImageJ software was used to quantitate the band
densities.Statistical Analysis
Univariate analyses were performed using the chi-square test for cate-
gorical variables and the t test for continuous variables. The data are
presented as the mean  standard deviation or standard error. A value of
P<.05 (2-sided) was considered to be statistically significant.RESULTS
miRNA-141 Blocks TGF-b–Triggered VIC Response
to Injury and Calcification
To determine the effect of miRNA-141 on cellular activa-
tion and induction of calcification, porcine VICs were trans-
fected with either a scrambled miRNA and stimulated with
TGF-b (scrambledmiRNA plus TGF-b) or miRNA-141 and
stimulated with TGF-b (miRNA-141 plus TGF-b) and com-
pared with nontransfected cells (control). The VICs were
also transfected with scrambled miRNA only or miRNA-
141 only and demonstrated a phenotype similar to that of
nontransfected controls (data not shown). TGF-b triggered
morphologic alterations, including transition from a spindle
to stellate cell morphology and dense cellular clustering
consistent with myofibroblastic transition in scrambled
miRNA-transfected VICs. However, this phenotype was
completely absent in miRNA-141–transfected VICs
(Figure 1, A). TGF-b further induced a synthetic osteoblas-
tic phenotype in scrambled miRNA–transfected VICs char-
acterized by calcification detected by alkaline phosphatase258 The Journal of Thoracic and Cardiovascular Surgactivity, which was also blocked by miRNA-141 overex-
pression (4.0  0.21 vs 3.55  0.18, P<.05; Figure 1, B).
miRNA-141 Blocks TGF-b–Triggered BMP-2
Signaling
To determine the mechanism of miRNA-141 inhibition
of VIC activation and calcification, the BMP-2 signaling
pathway was studied. Exposure of VICs to TGF-b resulted
in increased transcripts of BMP-2 (1.4  0.1 vs 1.0  0.1,
P<.05; Figure 2, A) and phosphorylation of downstream
extracellular signal-regulated kinase 1/2 (Figure E1), which
was partially reversed by overexpression of miRNA-141.
We have further demonstrated increased transcript levels
of downstream pro-osteogenic transcription factor RunX2
(3.4  0.1 vs 2.6  0.2, P< .05; Figure 2, B). Increased
RunX2 transcription levels were confirmed at protein levels
after TGF-b treatment in scrambled miRNA transfected and
subsequent reversal in miRNA-141 overexpressing VICs
(Figure E1).
BAV and TAV Patient Characteristics
The baseline patient characteristics are listed in Table 1.
Overall, 58.3% of the patients were women, 77.8% had hy-
pertension, 69.4% had hypercholesterolemia, and 33.3%
had diabetes mellitus. The BAV group was significantlyery c July 2012
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FIGURE 2. MicroRNA (miRNA)-141 represses bone morphogenetic
protein-2 (BMP-2) signaling in cultured valvular interstitial cells (VICs).
Transforming growth factor-b (TGF-b) treatment induced (A) BMP-2
and (B) runt-related transcription factor-2 (RunX2) transcript expression
compared with controls (mean  standard error; n ¼ 3/group). GADPH,
Glyceraldehyde-3-phosphate dehydrogenase.
Yanagawa et al Evolving Technology/Basic Scienceyounger than the TAV group (59.2  10.6 years vs 77.4 
6.2 years, P<.0001). No significant differences were found
in the preoperative cardiac risk factors between the BAVand
TAV patients. Of the BAV and TAV patients, 36.8% andTABLE 1. Demographic, clinical, and echocardiographic data
Variable BAV TAV P value
Patients (n) 19 17
Age (yr) 59.2  10.6 77.4  6.2 <.0001
Women 52.6 (10) 64.7 (11) .5
Risk factors
Hypertension 73.7 (14) 82.4 (14) .7
Hypercholesterolemia 57.9 (11) 82.4 (14) .2
Diabetes mellitus 26.3 (5) 41.2 (7) .5
Chronic kidney disease 5.3 (1) 11.8 (2) .6
Tobacco use 47.4 (9) 23.5 (4) .2
Medications
Statin 36.8 (7) 82.4 (14) .006
ACEi/ARB 31.6 (6) 64.7 (11) .09
b-Blocker 15.8 (3) 64.7 (11) .008
Echocardiographic parameters
LVEF (%) 56.8  7.3 58.5  5.0 .5
Mean gradient (mm Hg) 49.5  13.0 46.5  20.7 .6
Aortic valve area (cm2) 0.8  0.2 0.9  0.2 .7
Aortic insufficiency 40 (4) 20 (2) .6
Ascending aorta maximal
diameter (cm)
4.2  0.7 3.4  0.6 <.001
Data presented as percentages, with numbers of patients in parentheses, unless
otherwise noted. BAV, Bicuspid aortic valve; TAV, tricuspid aortic valve; ACEi,
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVEF,
left ventricular ejection fraction.
The Journal of Thoracic and Ca
E
T
/B
S82.4% were taking statin therapy (P ¼ .006) and 15.8%
and 64.7% were taking b-blockers (P ¼ .008) preopera-
tively, respectively.
Echocardiographic Measurement
Preoperative transthoracic echocardiographic measure-
ments, including left ventricular ejection fraction (56.8%
 7.3% vs 58.5%  5.0%, P ¼ .5), aortic valve area
(0.8 0.2 vs 0.9 0.2, P¼ .7), mean transvalvular gradient
(49.5  13.0 vs 46.5  20.7 mm Hg, P ¼ .6), and the pres-
ence of any degree of aortic insufficiency (40% vs 20%,
P ¼ .6), were not different between the BAV and TAV pa-
tients (Table 1). Thus, both groups of patients were consid-
ered to have severe AS. The diameter of the ascending aorta
was greater in the BAV patients than in the TAV patients
(4.2  0.7 cm vs 3.4  0.6 cm; P<.001).
Distinct miRNA Profiles in Human BAV and TAV
Comparative global profile analysis of miRNA expres-
sion was performed using a microarray containing 1583 hu-
man miRNA probes. Two patients in each group were
excluded at the microarray stage because of poor quality
RNA and hybridization data. The global miRNA profiles
were remarkably consistent and unique for bicuspid and tri-
cuspid tissue (n ¼ 8 patients/group; Figure 3, A). Microar-
ray analysis demonstrated differential expression of 34 of
1583 miRNA sequences in BAV compared with TAV. Eight
miRNAs were upregulated and 27 were downregulated
(Tables E1 and E2). Expression of miRNA-141 was down-
regulated 14.5-fold in BAV compared with TAV leaflets by
microarray. Confirmation with reverse transcriptase-
polymerase chain reaction demonstrated a decrease in
miRNA-141 expression in BAV compared with TAV pa-
tients (5.6  1.7 vs 8.2  1.5, P<.05; Figure 3, B).
BAV Leaflets Express Lower miRNA-14 and Greater
BMP-2 Signaling
We have demonstrated that miRNA-141 expression is as-
sociated with inhibition of BMP-2 signaling and calcifica-
tion in vitro and that human BAV leaflets have lower
miRNA-141 expression. Therefore, we sought to determine
whether BMP-2 signaling is increased in BAV tissue com-
pared with TAV tissue as a mechanistic explanation for
early clinical stenosis in patients with bicuspid valves. Leaf-
lets stained with von Kossa stain for calcification demon-
strated profound calcification as a proportion of leaflet
proper (Figure E2). Expression of a-SMA is associated
with a myofibroblastic phenotype in activated VICs. Immu-
nohistochemistry for a-SMA revealed positivity in close
proximity to areas of calcification, suggesting a cellular
source. Finally, BMP-2 staining revealed positivity in areas
adjacent to a-SMA and in close proximity to areas of valvu-
lar calcification in both bicuspid and tricuspid tissue
(Figure E2). Image analysis and quantification of von Kossardiovascular Surgery c Volume 144, Number 1 259
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FIGURE 3. MicroRNA (miRNA) profile in human bicuspid aortic valve
(BAV) versus tricuspid aortic valve (TAV) leaflets. A, Heat map showing
the global profile of the relative levels of miRNA expression in BAVs
and TAVs (n ¼ 8/group). B, miRNA-141 is significantly repressed in
BAV in microarray data (Left, mean  standard deviation; n ¼ 8/group),
which was also confirmed by reverse transcriptase polymerase chain reac-
tion (Right; mean  standard error; n ¼ 4/group).
FIGURE 4. Calcified bicuspid aortic valve (BAV) leaflets express greater
bone morphogenetic protein-2 (BMP-2) compared with tricuspid aortic
valve (TAV) leaflets. BAV leaflets expressed greater BMP-2 expression
than TAV leaflets and was found in close spatial association to areas of cal-
cification (mean  standard deviation; n ¼ 10–12/group).
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bicuspid and tricuspid leaflets (Figure E3). Immunoblot
analysis demonstrated that leaflet tissues from BAV
expressed a modest but significant increase in BMP-2 com-
pared with TAV leaflets, despite similar levels of calcifica-
tion (Figure 4). Taken together, theses data suggest that
activated myofibroblasts in BAV leaflets express greater
levels of BMP-2, which might account for the early calcifi-
cation seen clinically. Trends were seen toward greater ex-
pression of RunX2 and Dlx5 in BAV leaflets on immunoblot
analysis but this lacked statistical significance (data not
shown).DISCUSSION
In the present report, we have demonstrated that overex-
pression of miRNA-141 in cultured VICs blocks cellular ac-
tivation and osteoblastic transformation, likely through
a BMP-2–dependent mechanism. We then determined the
miRNA profile of BAVand TAV leaflets, demonstrating rel-
ative downregulation of miRNA-141 in stenotic bicuspid260 The Journal of Thoracic and Cardiovascular Surgleaflets. This was associated with increased BMP-2 expres-
sion. These findings suggest that loss of miRNA-141 regu-
lation of BMP-2–dependent calcification might underlie
altered susceptibility toward calcific AS observed in pa-
tients with BAV.
Cellular signals driving aortic valve calcification are rem-
iniscent of bone formation, and several lines of evidence
suggest that BMP-2 is a central regulator of calcification
in AS. Immunohistochemical staining has shown that ste-
notic human aortic valve leaflets express greater BMP-2
than nonstenotic leaflets.3 Treatment of cultured human
and porcine VICs with BMP-2 triggered cellular aggrega-
tion and calcification.15 This likely occurs through extracel-
lular signal-regulated kinase 1/2 and Smad signaling, with
downstream expression of pro-osteogenic transcription fac-
tor RunX2 and the sialoprotein osteopontin.8 However, not
all VICs are alike in their propensity to trigger BMP-2, be-
cause VICs from stenotic valves have greater BMP-2 than
VICs from nonstenotic valves after stimulation with Toll-
Like receptor-2/-4.16 Heterozygous Notch1 null mice de-
velop BAV, and heterozygous Notch1 mutations have been
shown in 2 families with BAV disease and severe AS.17,18
Nigam and Srivastava17 have also demonstrated that Notch1
represses the BMP-2–dependent osteoblastic commitment
of VICs, suggesting a possible mechanism for early calcifi-
cation. In the present report, we have demonstrated that
VICs from end-stage stenotic BAVs have increased BMP-2
signaling compared with stenotic TAVs and suggest
that lower miRNA-141 might be an important upstream
regulator.ery c July 2012
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cancer models and bone formation, miRNA-141 is involved
in regulation of cell fate decisions.11,19,20 In colorectal
cancer, miRNA-141 is a critical regulator of the
epithelial-to-mesenchymal transition, thereby inhibiting
migration and cancer invasion.19,20 In bone, miRNA-141
regulates BMP-2–induced preosteoblastic differentiation
by repression of distal-less homeobox 5.12 We have found
that miRNA-141 expression represses the VIC response to
injury simulated by TGF-b exposure, a known stimulus
for myofibroblast transformation.21 We have demonstrated
cellular aggregation, transition to a stellate phenotype,
and induction of calcification with TGF-b, which was com-
pletely reversed by miRNA-141. This is the first time that
miRNA-141 has been shown to regulate aortic VIC activa-
tion. Our data are consistent with a role of miRNA-141 in
regulation of cellular transition in multiple cell types. We
believe that such regulation occurs in aortic VICs upstream
of the BMP-2 pathway (Figure E4). However, the exact tar-
get of miRNA-141 in the BMP-2 pathway is unknown. A
search of miRNA-141 target sequences within known
BMP-2 signaling proteins using 2 separate miRNA target
prediction programs (TargetScan, version 4.1, available
from www.targetscan.org; and miRBase Targets, version
5, available from www.microrna.sanger.ac.uk/targets/v5/)
did not reveal any matches.
We have demonstrated global downregulation of miRNA
in stenotic bicuspid valves with greater than 3 times more
genes significantly downregulated compared with TAVs.
In the first report profiling miRNA in BAV compared
patients with stenotic versus regurgitant phenotypes, 7
miRNAs were significantly different statistically.22 Specif-
ically, miR-26a and miR-195 were reduced in the stenotic
valves, and human VICs treated with miR-26a or miR-
30b mimics showed decreased mRNA levels of calcifica-
tion-related genes, including BMP-2.That group compared
stenotic and insufficient BAV, whereas we compared ste-
notic BAV and TAV. Surprisingly, no overlap was found in
significantly altered miRNA in the 2 studies, which might
have been due to the specific miRNA microarrays and dif-
ferent experimental groups used for comparison.
No medical treatment is available for AS, and the only
definitive treatment is surgical replacement or transcatheter
implantation. An improved understanding of the underlying
pathogenetic mechanisms of valvular calcification could
lead to the development of targeted treatments to inhibit ste-
nosis development and delay or even avoid the need for
valve replacement. A focused miRNA treatment of AS
might take the form of antagomirs, complementary se-
quence oligonucleotides, which compete with the target
mRNA to bind miRNA. More than 30 clinical trials target-
ing miRNA have been performed to date for a range of dis-
eases, including heart failure, sepsis, melanoma, renal cell
carcinoma, and infection by hepatitis C and humanThe Journal of Thoracic and Caimmunodeficiency virus.23 Considering the robustness of
the role of miRNA-141 in cellular transformation and the
large number of potential targets, any potential treatment
would have to be carefully considered with regard to side
effects, with the most worrisome being oncologic.
Study Limitations
The present study had some important limitations. The
numbers of patients in the BAVand TAV groups were rela-
tively small, and high-quality RNAwas not obtained in ap-
proximately 33% of tissues, comparable to a recently
published experience.24 Given that several known calcium
signaling pathways exist and also that miRNAs might neg-
atively regulate up to 200 target sequences, the overall sig-
nificance of miRNA-141 regulation of BMP-2 remains to be
determined. As a caveat, we found a lower use of statins by
patients with BAV than by those with TAV (36.8% vs
82.4%). Statins have cholesterol-lowering and anti-
inflammatory properties. A recent meta-analysis has not
demonstrated any effect of statins on AS progression; how-
ever, the possible effects of statins on miRNA-141 function
are unknown.25 Finally, our studies of miRNA-141 regula-
tion of BMP-2–dependent calcification have established an
association but not causality. Additional work is needed to
confirm our findings and to establish a causal relationship
between miRNA-141 and calcification.
CONCLUSIONS
Our study has demonstrated that miRNA-141 represses
the VIC response to injury and calcification in cultured por-
cine VICs. This occurs at least in part through BMP-2–de-
pendent calcification. We have also shown that miRNA-141
is repressed in stenotic BAV compared with TAV leaflets
and is associated with increased BMP-2 expression. This
is the first study to demonstrate a potential regulatory role
for miRNA-141 in calcific AS.
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FIGURE E1. MicroRNA (miRNA)-141 represses transforming growth
factor-b (TGF-b) treatment-associated extracellular signal-regulated ki-
nase (ERK1/2) activation and runt-related transcription factor-2 (RunX2)
expression in cultured valvular interstitial cells (n ¼ 2/group). P, Phospho;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
FIGUREE2. Calcified bicuspid aortic valve (BAV) leaflets co-express greater a-smooth muscle actin (a-SMA) and bonemorphogenetic protein-2 (BMP-2)
positivity was in close spatial association to areas of calcification (Von Kossa stain; n ¼ 10–12/group).
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FIGUREE3. Bicuspid aortic valve (BAV) and tricuspid aortic valve (TAV)
leaflets expressed comparable levels of calcification (n ¼ 10–12/group).
FIGUREE4. ProposedmicroRNA (miRNA)-141 regulation of bone mor-
phogenetic protein-2 (BMP-2)–dependent calcification in aortic valve leaf-
lets. Upstream activators of valvular interstitial cells, such as transforming
growth factor-b (TGF-b), trigger BMP-2 signaling and transcription of the
pro-osteogenic transcription factor, runt-related transcription factor-2
(RunX2), leading to calcification and clinical aortic stenosis. miRNA-141
might be an important upstream regulator and, as such, the loss of expres-
sion such as in patients with bicuspid aortic valves (BAVs),might beget dys-
regulated BMP-2–dependent calcification.
TABLE E1. Upregulated miRNA expression in human BAV vs TAV
miRNA Fold change (BAV/TAV) P value
hsa-miR-151-3p 16.44 .01
hsa-miR-152 15.87 .003
hsa-miR-030e 14.80 .007
hsa-miR-032 8.78 .02
hsa-miR-145 8.48 .008
hsa-miR-768-5p 3.86 .03
hsa-miR-190 3.31 .04
hsa-miR-373* 1.19 .004
miRNA, MicroRNA; BAV, bicuspid aortic valve; TAV, tricuspid aortic valve.
TABLEE2. Downregulated miRNA expression in human BAV vs TAV
miRNA Fold change (BAV/TAV) P value
hsa-miR-370 0.83 .020
hsa-miR-022 0.56 .04
hsa-miR-1972 0.54 .04
hsa-miR-330-5p 0.47 .04
hsa-miR-566-pre 0.39 .05
hsa-miR-1469 0.38 .03
hsa-miR-1908 0.30 .01
hsa-miR-648-pre 0.23 .01
hsa-miR-637 0.23 .01
hsa-miR-1282 0.23 .004
hsa-miR-622 0.18 .05
hsa-miR-486-3p 0.15 .04
hsa-miR-187 0.14 .05
hsa-miR-1909* 0.12 .03
hsa-miR-564 0.08 .01
hsa-miR-141 0.07 .04
hsa-miR-027a 0.07 .009
hsa-miR-194* 0.05 .01
hsa-miR-125b-1-pre 0.00 .003
hsa-miR-551a-pre 0.00 .03
hsa-miR-575 0.00 .03
hsa-miR-585-pre 0.00 .03
hsa-miR-211-pre 0.00 .05
hsa-miR-449b* 0.00 .05
hsa-miR-124-3-pre 0.00 .05
hsa-miR-185-pre 0.00 .05
hsa-miR-1202 0.00 .05
miRNA, MicroRNA; BAV, bicuspid aortic valve; TAV, tricuspid aortic valve.
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